The Registry of Toxic Effects of Chemical Substances

Dibenz (a,h) anthracene

RTECS #: HN2625000

CAS #: 53-70-3

UPDATE: May 2005 MW: 278.36 MF: C22H14


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. MUTATION DATA:
  3. TUMORIGENIC DATA:
  4. ACUTE TOXICITY DATA:
  5. OTHER MULTIPLE DOSE DATA:
  6. REVIEWS:
  7. STANDARDS AND REGULATIONS:
  8. STATUS IN FEDERAL AGENCIES:
  9. REFERENCES:

SYNONYMS:

  1. 1,2:5,6 - Benzanthracene
  2. DB (a,h) A
  3. 1,2,5,6 - Dba
  4. 1,2,5,6 - Dibenzanthraceen (Dutch)
  5. Dibenzo (a,h) anthracene
  1. 1,2:5,6 - Dibenzoanthracene
  2. RCRA waste number U063
  3. 1,2:5,6 - Dibenzanthracene
  4. 1,2:5,6 - Dibenz (a) anthracene


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE 		DOSE REFERENCE
cytogenetic analysis inhalation
Drosophila melanogaster 		2,700 mg/L GENTAE 33,337,1948
cytogenetic analysis hamster fibroblast 1 mmol/L PJACAW 53,46,1977
DNA adduct Escherichia coli 10 µmol/L MUREAV 89,95,1981
DNA adduct hamster embryo 360 nmol/L CBINA8 22,257,1978
DNA adduct hamster lung 1 mg/L CBINA8 4,389,1971/1972
DNA adduct human embryo 360 nmol/L CBINA8 22,257,1978
DNA adduct mouse liver 6 µmol/L JJIND8 62,947,1979
DNA adduct skin
mouse 		40 µmol/kg IJCNAW 23,201,1979
DNA adduct mouse other cell types 1 mg/L CBINA8 4,389,1971/1972
DNA adduct mouse embryo 510 nmol/L IJCNAW 9,349,1972
DNA adduct oral
mouse 		6.3 mg/kg/9 week- intermittent JJATDK 15,59,1995
DNA adduct intratracheal
rat 		25,560 µg/kg MUREAV 312,165,1994
DNA adduct salmon testis 5 µg/1 hour- continuous BIJOAK 110,159,1968
DNA damage Escherichia coli 1,207.1 µg/L/3 hour (+enzymatic activation step) MUREAV 515,85,2002
DNA damage hamster fibroblast 5 mg/L/24 hour BCPCA6 20,1297,1971
DNA damage hamster kidney 5 mg/L BCPCA6 20,1297,1971
DNA damage mammal (species unspecified) lymphocyte 2 nmol/L JMOBAK 5,521,1962
DNA repair Escherichia coli 25 µg/well MUREAV 46,53,1977
unscheduled DNA synthesis human fibroblast 100 µmol/L CBPCEE 86,399,1987
unscheduled DNA synthesis human other cell types 10 mg/L CNREA8 38,2091,1978
unscheduled DNA synthesis human HeLa cell 100 nmol/L CNREA8 38,2621,1978
unscheduled DNA synthesis oral
mouse 		6.3 mg/kg/9 week- intermittent JJATDK 15,59,1995
unscheduled DNA synthesis other fish other cell types 100 µmol/L CBPCEE 86,399,1987
mutation in microorganisms hamster lung 56,400 nmol/L (+enzymatic activation step) MUREAV 46,27,1977
mutation in microorganisms mouse lymphocyte 4,250 µg/L (+enzymatic activation step) MUREAV 106,101,1982
mutation in microorganisms Neurospora crassa 500 ppm (-enzymatic activation step) ANYAA9 71,1072,1958
mutation in microorganisms Salmonella typhimurium 5 µg/plate (-enzymatic activation step) MUREAV 174,247,1986
micronucleus test intraperitoneal
mouse 		500 mg/kg MUREAV 389,3,1997
micronucleus test oral
mouse 		6.3 mg/kg/9 week- intermittent JJATDK 15,59,1995
micronucleus test intratracheal
rat 		25,500 µg/kg/16 hour- intermittent MUREAV 326,147,1995
gene conversion and mitotic recombination Drosophila melanogaster 2 mmol/L MUREAV 514,193,2002
mutation in mammalian somatic cells hamster lung 500 µg/L MUREAV 136,65,1984
mutation in mammalian somatic cells human lymphocyte 54 µg/L MUREAV 371,123,1996
morphological transform hamster embryo 2,500 µg/L CNREA8 32,1391,1972
morphological transform hamster kidney 25 µg/L TOLED5 7,143,1980
morphological transform mouse fibroblast 500 µg/L AETODY 1,133,1980
morphological transform mouse embryo 100 µg/L JNCIAM 52,1167,1974
morphological transform oral
rat 		200 mg/kg CNREA8 40,1157,1980
morphological transform rat embryo 100 µg/L JNCIAM 51,799,1973
other mutation test systems hamster lung 1 mg/L CBINA8 4,389,1971/1972
other mutation test systems mouse other cell types 1 mg/L CBINA8 4,389,1971/1972
other mutation test systems mouse embryo 510 nmol/L IJCNAW 9,349,1972
phage inhibition capacity Escherichia coli 2 µg/well MUREAV 260,349,1991
sister chromatid exchange intraperitoneal
hamster 		900 mg/kg/24 hour MUREAV 66,65,1979
sister chromatid exchange intratracheal
rat 		51,150 µg/kg MUREAV 312,165,1994
sex chromosome loss and nondisjunction parenteral
Drosophila melanogaster 		5 mmol/L EJGCA9 4,400,1975
sex chromosome loss and nondisjunction inhalation
Drosophila melanogaster 		2,700 mg/L GENTAE 33,337,1948


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
implant
mouse 		lowest published toxic dose: 80 mg/kg Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		BJCAAI 11,212,1957
implant
mouse 		toxic dose : 14 mg/kg Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application 		AJPAA4 16,287,1940
implant
mouse 		toxic dose : 200 mg/kg Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Bronchogenic carcinoma

Tumorigenic: Tumors at site of application 		AJCAA7 36,201,1939
implant
mouse 		toxic dose : 100 mg/kg Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors

Tumorigenic: Tumors at site of application 		BMBUAQ 14,147,1958
intramuscular
pigeon 		lowest published toxic dose: 6 mg/kg Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Tumorigenic: Tumors at site of application 		JNCIAM 32,905,1964
intrarenal
frog 		lowest published toxic dose: 12 mg/kg Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Kidney, Ureter, and Bladder: Kidney tumors 		CNREA8 24,1969,1964
intratracheal
rat 		lowest published toxic dose: 100 mg/kg Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		GISAAA 31(7),12,1966
intravenous
guinea pig 		lowest published toxic dose: 30 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Tumorigenic: Tumors at site of application 		JNCIAM 13,705,1952
intravenous
mouse 		lowest published toxic dose: 40 mg/kg Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Liver: Tumors 		PHRPA6 54,1158,1939
multiple
mouse 		lowest published toxic dose: 40 mg/kg/12 day- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Tumorigenic: Tumors at site of application 		PHRPA6 52,637,1937
oral
mouse 		lowest published toxic dose: 4,160 mg/kg/26 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		JPBAA7 49,21,1939
oral
mouse 		toxic dose : 4,520 mg/kg/36 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Gastrointestinal: Tumors 		JNCIAM 1,17,1940
subcutaneous
guinea pig 		lowest published toxic dose: 250 mg/kg/24 day- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Tumorigenic: Tumors at site of application 		AKBNAE 51,112,1938
subcutaneous
mouse 		lowest published toxic dose: 445 µg/kg Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application 		CRNGDP 11,1721,1990
subcutaneous
mouse 		toxic dose : 78 µg/kg Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application 		JNCIAM 3,503,1943
subcutaneous
mouse 		toxic dose : 6 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Tumorigenic: Tumors at site of application 		IJCNAW 32,765,1983
subcutaneous
mouse 		toxic dose : 400 mg/kg/10 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application 		IJCNAW 2,500,1967
subcutaneous
rat 		toxic dose : 135 mg/kg/9 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Tumorigenic: Tumors at site of application 		PSEBAA 68,330,1948
skin
mouse 		lowest published toxic dose: 1,200 mg/kg/50 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application 		14JTAF -,275,1965
skin
mouse 		toxic dose : 6 µg/kg Tumorigenic: Neoplastic by RTECS criteria

Skin and Appendages: Tumors 		CNREA8 20,1179,1960
skin
mouse 		toxic dose : 400 mg/kg/40 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Skin and Appendages: Tumors 		CNREA8 22,78,1962


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intravenous
mouse 		lowest published lethal dose: 10 mg/kg N/R JNCIAM 1,225,1940


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
unreported route
mouse 		lowest published toxic dose: 180 mg/kg/12 day- intermittent Immunological Including Allergic: Uncharacterized (multiple organ involvement) TOXID9 48,13,1999


REVIEWS:

ORGANIZATION STANDARD
REFERENCE
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 3,178,1973
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 32,299,1983
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 32,299,1983
International Agency for Research on Cancer (IARC) Cancer Review Group 2A IMSUDL 7,56,1987
TOXICOLOGY REVIEW
MUREAV 544,397,2003
TOXICOLOGY REVIEW
MUREAV 540,89,2003
TOXICOLOGY REVIEW
MUREAV 558,155,2004
TOXICOLOGY REVIEW
MUREAV 558,7,2004
TOXICOLOGY REVIEW
TOLED5 140-141,353,2003
TOXICOLOGY REVIEW
MUREAV 567,227,2004
TOXICOLOGY REVIEW
MUREAV 567,109,2004
TOXICOLOGY REVIEW
MUREAV 567,401,2004
TOXICOLOGY REVIEW
MUREAV 567,151,2004
TOXICOLOGY REVIEW
MUREAV 567,151,2004
TOXICOLOGY REVIEW
MUREAV 567,347,2004


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE
Occupational Exposure Limit - FRANCE Carcinogen, JAN1993
Occupational Exposure Limit - GERMANY Carcinogen, JAN1999
Occupational Exposure Limit - NORWAY time-weighted average 0.04 mg/m3, JAN1999
Occupational Exposure Limit - POLAND time-weighted average 0.004 mg/m3, JAN1999


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE
N/R N/R N/R


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE
ATSDR TOXICOLOGY PROFILE (NTIS** PB/95/264370)
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; Cell transform.-SA7/F344 rat
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-BALB/c-3T3; SHE-focus assay
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-C3H/10T1/2; Cell transform.-mouse embryo
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-RLV F344 rat embryo
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE; N crassa-forward mutation
EPA GENETOX PROGRAM 1988, Positive: Histidine reversion-Ames test
EPA GENETOX PROGRAM 1988, Positive: D melanogaster Sex-linked lethal
EPA GENETOX PROGRAM 1988, Positive: V79 cell culture-gene mutation
EPA GENETOX PROGRAM 1988, Positive/dose response: SHE-clonal assay
EPA GENETOX PROGRAM 1988, Inconclusive: Cell transform.-mouse prostate; In vivo SCE-nonhuman
EPA GENETOX PROGRAM 1988, Inconclusive: In vitro UDS-human fibroblast
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
On EPA IRIS database
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NIOSH Analytical Method, 1994: Polynuclear aromatic hydrocarbons by HPLC, 5506; by GC, 5515
NTP 11th Report on Carcinogens,2004:Reasonably anticipated to be a human carcinogen


REFERENCES:

CODEN
REFERENCE
14JTAF "Mycotoxins in Foodstuffs, Proceedings of the Symposium held at the Massachusetts Institute of Technology, 1964," Wogan, G.N., ed., Cambridge, MA, MIT Press, 1965
AETODY Advances in Modern Environmental Toxicology. (Senate Press, Inc., P.O. Box 252, Princeton Junction, NJ 08550) V.1- 1980-
AJCAA7 American Journal of Cancer. (New York, NY) V.15-40, 1931-40. For publisher information, see CNREA8.
AJPAA4 American Journal of Pathology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1925-
AKBNAE Arkhiv Biologicheskikh Nauk. Archives of Biological Sciences. For French translation, see ASBUAN. (Moscow, USSR) V.1-64, 1892-1941. Discontinued.
ANYAA9 Annals of the New York Academy of Sciences. (New York Academy of Sciences, 2 E. 63rd St., New York, NY 10021) V.1- 1877-
BCPCA6 Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1958-
BIJOAK Biochemical Journal. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1906-
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
BMBUAQ British Medical Bulletin. (Longman Group UK Ltd., Longman House, Burnt Mill, Harlow, Essex CM20 2JE, UK) V.1- 1943-
CBINA8 Chemico-Biological Interactions. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1969-
CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983-
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
EJGCA9 Egyptian Journal of Genetics and Cytology. (Egyptian Soc. of Genetics, c/o Alexandria Univ., Faculty of Agriculture, Dept. of Genetics, Alexandria, Egypt) V.1- 1972-
GENTAE Genetics. (Genetics Business Office, POB 64025, Baltimore, MD 21264) V.1- 1916-
GISAAA Gigiena i Sanitariya. For English translation, see HYSAAV. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1- 1936-
IJCNAW International Journal of Cancer. (International Union Against Cancer, 3 rue du Conseil- General, 1205 Geneva, Switzerland) V.1- 1966-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979-
JJATDK JAT, Journal of Applied Toxicology. (John Wiley & Sons Ltd., Baffins Lane, Chichester, W. Sussex PO19 1UD, UK) V.1- 1981-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JMOBAK Journal of Molecular Biology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JPBAA7 Journal of Pathology and Bacteriology. (London, UK) V.1-96, 1892-1968. For publisher information, see JPTLAS.
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
PHRPA6 Public Health Reports. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) V.1- 1878-
PJACAW Proceedings of the Japan Academy. (Tokyo, Japan) V.21-53, 1945-77. For publisher information, see PJABDW.
PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04-
TOLED5 Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977-
TOXID9 Toxicologist. (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-

RTECS Compound Description:
   Tumorigen
   Mutagen

Click Here for Additional Information about RTECS